5th Annual RAS-Targeted Drug Development Summit

With the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable! However, with so many KRAS G12C drugs in clinic, the field is now turning its eyes to the next generation of RAS therapies, specifically those that can target more mutations, more RAS isoforms, and more indications.

And so, the 5th RAS Targeted Drug Development Summit arrives as the only industry-dedicated, end-to-end forum to accelerate your best-in-class RAS therapies from conception through to commercialization.

Time: 08:30 – 18:00

Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States

Prices:
USD 2599.00 – USD 6046.00

Speakers: Arjun Balar, Vice President – Global Clinical Development, Loxo Oncology, Saskia Brachmann, Associate Director and Senior Global Lead, Novartis, Emily Chan, Medical Director, Clinical Research, Amgen, Nicholas Endres, Principal Scientist, Genentech, Antreas Hindoyan, Director, Clinical Biomarkers and Diagnostics, Amgen , and more.